Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM) [Phase 3]

View source ↗

Summary

Phase 3 randomized, double-blind, placebo-controlled trial to assess the efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL subcutaneous immunotherapy in adults …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Asthma
• Rhinoconjunctivitis

Drugs mentioned

• PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy (house dust mite extract immunotherapy)

Snippet

Sponsor: HAL Allergy | Conditions: House Dust Mite Allergy, House Dust Mite Rhinitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING